Clinical Trials
3 trialsNCT06202066 2026-05-28
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT01824875 2026-02-25
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT05040360 2025-12-15
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
SWOG Cancer Research Network
Phase 2 Recruiting